Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica
Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, has expanded its PROST!
- Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, has expanded its PROST!
- Phase 2 clinical trial (NCT number: NCT05436652 ) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.
- For the rheumatology program, a fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.
- To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .